Relmada Therapeutics Inc (RLMD) - Total Liabilities
Based on the latest financial reports, Relmada Therapeutics Inc (RLMD) has total liabilities worth $16.63 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore RLMD year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Relmada Therapeutics Inc - Total Liabilities Trend (2012–2025)
This chart illustrates how Relmada Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does Relmada Therapeutics Inc generate to measure how efficiently the company converts operating cash flow to free cash.
Relmada Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Relmada Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Skyworks Solutions Inc
SA:S1SL34
|
Russia | RUB2.11 Billion |
|
TELUS International
TO:TIXT
|
Canada | CA$2.75 Billion |
|
Ningbo Shenglong Automotive Powertrain System Co Ltd
SHG:603178
|
China | CN¥959.67 Million |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
China | CN¥3.69 Billion |
|
Qinghai Jinrui Mineral Development Co Ltd
SHG:600714
|
China | CN¥79.36 Million |
|
Gan Yuan Foods Co Ltd
SHE:002991
|
China | CN¥384.61 Million |
|
Unity Bancorp Inc
NASDAQ:UNTY
|
USA | $2.67 Billion |
|
Allied Supreme Corp
TW:4770
|
Taiwan | NT$2.45 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Relmada Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RLMD market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Relmada Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Relmada Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Relmada Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.49 Million | -27.24% |
| 2024-12-31 | $10.30 Million | -15.57% |
| 2023-12-31 | $12.19 Million | -2.20% |
| 2022-12-31 | $12.47 Million | -17.21% |
| 2021-12-31 | $15.06 Million | +19.50% |
| 2020-12-31 | $12.60 Million | +764.53% |
| 2019-12-31 | $1.46 Million | -82.97% |
| 2018-12-31 | $8.56 Million | +521.89% |
| 2017-12-31 | $1.38 Million | -57.00% |
| 2016-12-31 | $3.20 Million | -79.45% |
| 2015-12-31 | $15.58 Million | 0.00% |
| 2014-12-31 | $15.58 Million | -42.01% |
| 2014-06-30 | $26.87 Million | 0.00% |
| 2013-12-31 | $26.87 Million | +384025.37% |
| 2012-12-31 | $7.00K | -- |
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, whic… Read more